Investor Relations Home
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$35.54
Change (%) Stock is Up 0.15 (0.42%)
Volume917,271
Data as of 08/22/17 2:06 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
08/09/17The Medicines Company Reports Second Quarter 2017 Business and Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 9, 2017-- The Medicines Company (NASDAQ:MDCO) today reported its financial results for the second quarter ended June 30, 2017, and provided an update on its clinical and operational activities. Second Quarter 2017 Highlights and Projected Milestones Meropenem-Vaborbactam The Company announced positive results from a planned, interim analysis of the TANGO-2 trial of its fix... 
Printer Friendly Version
07/31/17The Medicines Company to Announce Second-Quarter 2017 Financial Results on August 9
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 31, 2017-- The Medicines Company (NASDAQ:MDCO) will host a conference call on Wednesday, August 9, 2017, at 8:30 a.m., Eastern Daylight Time, to discuss its second-quarter 2017 financial results and operational developments. A live audio webcast of the conference call may be accessed in the Investors section of The Medicines Company website. A replay of the webcast will be available on the web... 
Printer Friendly Version
07/25/17The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, Carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE
—Trial stopped early following recommendation by independent Data Safety and Monitoring Board— —Meropenem-vaborbactam demonstrated improved clinical cure rates across all infection types and reduced rate of renal adverse events compared to best available therapy— —The Company also announces VabomereTM as the U.S. and European trade name for meropenem-vaborbactam— PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 25, 2017-- The Med... 
Printer Friendly Version
05/30/17The Medicines Company to Present Data at ASM Microbe 2017 on Infectious Disease Portfolio Including Late-Stage Investigational Antibiotic Meropenem-Vaborbactam
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 30, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products and late-stage product candidates will be featured in presentations at the American Society for Microbiology’s ASM Microbe 2017 to be held June 1-5, 2017 in New Orleans. The Medicines Company’s infectious disease research and product development is focused on the most serious multi-drug resist... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.